Oxadendralenes in Asymmetric Organocatalysis for the Construction of Tetrahydroisochromenes

Niels Hammer, Lars A. Leth, Julian Stiller, Magnus E. Jensen and Karl Anker Jørgensen*

Department of Chemistry, Aarhus University DK-8000 Aarhus C, Denmark e-mail: kaj@chem.au.dk

Contents

1. General methods	S2
2. Synthesis of starting materials	S3
3. Synthesis of the cyclohexadiene dienal 3b	S7
 Synthesis of the tetrahydroisochromenes 5a-r 	S8
5. Synthesis of the tetrahydroisochromenes 6a-e	S14
6. Transformations	S16
7. X-Ray structures	S18
8. NMR spectra	S24
9. UPC ² traces	S61

1. General methods

NMR spectra were acquired on a Varian AS 400 spectrometer or a Bruker AVANCE III HD spectrometer, running at 400 MHz for ¹H and 100 MHz for ¹³C, respectively. Chemical shifts (δ) are reported in ppm relative to residual solvent signals (CHCl₃, 7.26 ppm for ¹H NMR, CDCl₃, 77.0 ppm for ¹³C NMR, DMSO-d₆, 2.50 ppm for ¹H NMR, CDCl₃, 39.52 ppm for ¹³C NMR). The following abbreviations are used to indicate the multiplicity in NMR spectra: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad resonance. ¹³C NMR spectra were acquired on a broad band decoupled mode. Mass spectra were recorded on a Bruker MicroTOF-Q High-Performance LC-MS system. Analytical thin layer chromatography (TLC) was performed using pre-coated aluminium-backed plates (Merck Kieselgel 60 F254) and visualized by ultraviolet irradiation, KMnO₄ or *p*-anisaldehyde dip. Optical rotations were measured on a Bellingham+Stanley ADP440+ polarimeter. The enantiomeric excess (ee) of the products was determined by Ultraperformance Convergence Chromatography (ACQUITY UPC) using Daicel Chiralpak IA, IB, IC and ID columns as chiral stationary phases (columns were kept at 40 °C during measuring). Unless otherwise noted, analytical grade solvents and commercially available reagents were used without further purification. Racemic samples of the tetrahydroisochromenes 5 were prepared using a racemic mixture of enantiomers of TMS-diphenyl prolinol catalyst A (20 mol%) in CHCl₃, while racemic samples of the tetrahydroisochromenes 6 were prepared by mixing the two enantiomers. For NMR characterization * denotes the minor isomer, ⁺ denotes overlap of signals of both isomers, whereas no sign denotes major isomer.

2. Synthesis of starting materials

Overview:



General procedure:

A flask was charged with 4Å activated molecular sieves (14 g) and dry toluene (87 mL) were added. Subsequently dimethyl glutaconate I (7.0 mmol, 1.0 equiv.), aldehyde IV (8.4 mmol, 1.2 equiv.), piperidine (3.5 mmol, 0.5 equiv.) and AcOH (3.5 mmol, 0.5 equiv.) were added accordingly. The reaction mixture was refluxed for 24 h until full conversion. The reaction was quenched by addition of sat. aq. NH₄Cl (excess). After filtration, the filtrate was extracted with EtOAc and washed with sat. NaHCO₃. Finally, the organic phase was dried over MgSO₄ and the solvent was removed to yield the crude of II as a yellow oil. The crude product II was used for the next step without further purification.

Under inert atmosphere II was solved in dry toluene (20 mL). The mixture was cooled to -78 °C and DIBAL-H (1.0 M in toluene, 35 mmol, 5.0 equiv.) was added dropwise. The mixture was stirred at -78 °C for 5 h to achieve full conversion (TLC). The reaction was quenched by adding EtOAc (5 mL) followed by Rochelles Salt (50 mL). The mixture was then allowed to warm to rt and stirred vigorously overnight. The biphasic mixture was separated and the aqueous layer was extracted with EtOAc (2 x 25 mL) and dried over MgSO₄. The solvent was removed and the crude product was purified by FC (Et₂O:CH₂Cl₂ 1:1), yielding III as a bright yellow solid.

(*E*)-4-((*E*)-Benzylidene)pent-2-ene-1,5-diol IIIa was synthesized following the general procedure and obtained in 67% yield, E/Z 3/1. ¹H NMR (400 MHz, CDCl₃) δ 7.40 – 7.24 (m, 5H⁺), 6.76 – 6.64 (m, 2H, 1H^{*}), 6.40 (d, *J* = 15.9 Hz, 1H^{*}), 6.14 (m, *J* = 16.1, 5.8 Hz, 1H⁺), 4.49 – 4.44 (m, 2H⁺), 4.30 (dd, *J* = 5.8, 1.5 Hz, 2H^{*}), 4.24 (dd, *J* = 5.8, 1.6 Hz, 2H), 1.69 (s, 2H⁺).¹³C NMR (100 MHz, CDCl₃) δ 137.0^{*}, 136.6, 136.4⁺, 134.2^{*}, 133.4^{*}, 130.6, 129.9, 129.3 (2C), 128.9 (2C^{*}), 128.8^{*}, 128.3 (2C^{*}), 128.2 (2C), 127.4^{*}, 127.1, 126.6, 64.7, 63.7, 63.5^{*}, 57.6^{*}. HRMS (ESI+) *m/z* calcd. for C₁₂H₁₄O₂Na [M+Na]⁺:

213.0886; found: 213.0886.

(2*E*)-4-(3-Bromobenzylidene)pent-2-ene-1,5-diol IIIb was synthesized following the general procedure and obtained in 68% yield, E/Z 3/1. ¹H NMR (400 MHz, CDCl₃) δ 7.50 (dd, *J* = 1.8 Hz, 1H*), 7.43 – 7.33 (m, 2H, 1H*), 7.31 – 7.28 (m, 1H*), 7.24 – 7.16 (m, 2H, 1H*), 6.67 – 6.53 (m, 2H, 1H*), 6.34 (d, *J* = 15.9 Hz, 1H*), 6.13 (m, 1H⁺), 4.43 (s, 2H), 4.41 (s, 2H*), 4.27 (dd, *J* = 5.7, 1.4 Hz, 2H*), 4.22 (dd, *J* = 5.9, 1.5 Hz, 2H), 2.30 (s, 2H⁺).¹³C NMR (100 MHz, CDCl₃) δ 138.7, 138.4*, 138.2*, 137.6, 132.9*, 132.4*, 132.0, 131.7*, 131.4, 130.3*, 130.0, 129.8*, 129.7, 129.6*, 127.9, 127.9, 127.5*, 125.9, 122.3*, 122.2, 64.4, 63.6, 63.4*, 57.4*. HRMS (ESI+) *m/z* calcd. for C₁₂H₁₃BrO₂Na [M+Na]⁺: 290.9991; found: 290.9993.

OH OH

(2*E*)-4-(4-Bromobenzylidene)pent-2-ene-1,5-diol IIIc was synthesized following the general procedure and obtained in 77% yield, E/Z 4/1. ¹H NMR (400 MHz, DMSO- d_6) δ 7.55 (d, *J* = 8.0 Hz, 2H⁺), 7.39 (d, *J* = 8.2 Hz, 2H⁺), 7.23 (d, *J* = 8.1 Hz, 2H), 6.62 – 6.50 (m, 2H, 1H⁺), 6.29 (d, *J* = 15.9 Hz, 1H⁺), 6.12 (dt, *J* = 15.9, 5.3 Hz, 1H⁺), 6.02 (dt, *J* = 16.1, 4.9 Hz, 1H), 5.05 (t, *J* = 5.6 Hz, 1H⁺), 4.79 (m, *J* = 5.6 Hz, 1H⁺), 4.22 (d, *J* = 5.5 Hz, 2H), 4.16 (d, *J* = 4.8 Hz, 2H⁺), 4.12 – 4.05 (m,

2H*), 4.03 (t, J = 5.1 Hz, 2H). ¹³**C NMR** (100 MHz, DMSO- d_6) δ 139.3*, 138.4, 136.3, 136.0*, 132.6, 131.5*, 131.3*, 131.2 (2C), 131.1 (2C⁺), 131.0 (2C⁺), 130.4*, 124.4, 123.4, 120.3*, 119.7, 62.1, 61.6*, 61.5, 56.1*. **HRMS** (ESI+) m/z calcd. for C₁₂H₁₃BrO₂Na [M+Na]⁺: 290.9991; found: 290.9991.

 $\begin{array}{c} \textbf{(2E)-4-(4-Methoxybenzylidene)pent-2-ene-1,5-diol IIId was synthesized following the} \\ \textbf{(2E)-4-(4-Methoxybenzylidene)pent-2-ene-1,5-diol IIId was synthesized following the} \\ \textbf{general procedure and obtained in 58\% yield as a pure (E)-isomer. ¹H NMR (400 MHz, CDCl₃) <math>\delta$ 7.29 – 7.21 (m, 2H), 6.95 – 6.87 (m, 2H), 6.72 – 6.66 (m, 1H), 6.66 (s, 1H), 6.10 (dt, J = 16.1, 6.0 Hz, 1H), 4.42 (d, J = 1.1 Hz, 2H), 4.22 (dd, J = 6.0, 1.4 Hz, 2H), 3.84 (s, 3H), 3.10 (s, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 158.7, 135.0, 130.6 (2C), 130.2, 129.6, 129.2, 126.8, 113.6 (2C), 64.9, 63.7, 55.2. HRMS (ESI+) m/z calcd. for C₁₃H₁₆O₃Na [M+Na]⁺: 243.0992; found: 243.0994.

(2E,4E)-4-(Furan-2-ylmethylene)pent-2-ene-1,5-diol IIIe was synthesized following the general procedure and obtained in 67% yield as a pure (E)-isomer. ¹H NMR (400 MHz, CDCl₃) δ 7.43 (d, J = 1.8 Hz, 1H), 7.22 (m, 1H), 6.40 (dt, J = 3.5, 1.8 Hz, 1H), 6.35 (m, 2H), 6.06 (dt, J = 16.1, 5.9 Hz, 1H), 4.38 (d, J = 1.2 Hz, 2H), 4.27 (dd, J = 6.0, 1.6 Hz, 2H), 2.36 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 152.6, 142.7, 133.8, 130.6, 127.1, 116.7, 111.7, 111.4, 64.5, 63.9. HRMS (ESI+) m/z

calcd. for $C_{10}H_{12}O_3Na[M+Na]^+$: 203.0679; found: 203.0679.

2.2. Oxadendralenic dienals 1a-e



General procedure:

A solution of III (1.5 mmol, 1 equiv.) in CH₂Cl₂ (16.5 mL) was cooled to 0 °C and Dess-Martin Periodinane (4.5 mmol, 3 equiv.) was added. The reaction mixture was allowed to warm to rt and stirred overnight to achieve full conversion. After that, the mixture was cooled to 0 °C again and diluted with Et₂O (16.5 mL). Subsequently a 1:1:1 mixture of sat. aq. Na₂S₂O₃ (5.0 mL), sat. aq. NaHCO₃ (5.0 mL) and H₂O (5.0 mL) were added slowly. The reaction mixture was warmed to rt and stirring vigorously for 2 h. The phases were separated and the aqueous layer was extracted with Et₂O (4 x 25 mL). The combined organic layers were dried over Na2SO4 and the solvent was removed. The resulting orange solid was purified by FC (pentane:EtOAc 1:10 to 1:5) yielding **1** as a bright yellow solid.

The major isomer of the oxadendralenic dienals is *E* according to the relative configuration obtained via Xray analysis (Supporting Information Section 7.1.).

(2E)-4-Benzylidenepent-2-enedial 1a was synthesized following the general procedure and obtained in 62% yield as a pure (E)-isomer. ¹H NMR (400 MHz, CDCl₃) δ 9.77 (d, J = 2.1 Hz, 1H), 9.65 (d, J = 7.5 Hz, 1H), 7.62 (s, 1H), 7.51 (m, J = 1.5 Hz, 5H), 7.36 (ddd, J = 16.1, 2.1, 1.0 Hz, 1H), 7.23 (dd, J = 16.3, 7.5 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 194.4, 191.8, 155.3, 141.5, 134.7, 133.9, 133.7, 131.2, 130.5 (2C), 129.1 (2C). **HRMS** (ESI+) m/z calcd. for $C_{12}H_{11}O_2[M+H]^+$: 187.0754; found: 187.0752.

(E)-4-((E)-3-Bromobenzylidene)pent-2-enedial 1b was synthesized following the general procedure and obtained in 67% yield as a pure (*E*)-isomer. ¹H NMR (400 MHz, CDCl₃) δ 9.76 (d, J = 2.0 Hz, 1H), 9.65 (d, J = 7.1 Hz, 1H), 7.64 (m, 2H), 7.53 (s, 1H), 7.45 – 7.36 (m, 2H), 7.32 -7.26 (m, 1H), 7.21 (dd, J = 16.2, 7.1 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 194.1, 191.4, 152.8, 140.5, 135.6, 135.3, 135.0, 133.9, 133.0, 130.6, 128.7, 123.2. HRMS (ESI+) m/z calcd.

for C₁₂H₁₀BrO₂ [M+H]⁺: 264.9859; found: 264.9857.



(E)-4-((E)-4-Bromobenzylidene)pent-2-enedial 1c was synthesized following the general procedure and obtained in 40% yield as a pure (*E*)-isomer. ¹H NMR (400 MHz, CDCl₃) δ 9.75 (d, J = 2.0 Hz, 1H), 9.65 (d, J = 7.0 Hz, 1H), 7.69 - 7.63 (m, 2H), 7.53 (s, 1H), 7.39 - 7.34 (m, 2H), 7.32 – 7.26 (m, 1H), 7.21 (dd, J = 16.2, 7.0 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 193.9, 191.4, 153.2, 140.7, 135.1, 134.4, 132.6, 132.5 (2C), 131.7 (2C), 125.9. HRMS (ESI+) m/z calcd. for C₁₂H₁₀BrO₂ [M+H]⁺: 264.9859; found: 264.9855.

(E)-4-((E)-4-Methoxybenzylidene)pent-2-enedial 1d was synthesized following the general procedure and obtained in 53% yield as a pure (E)-isomer. ¹H NMR (400 MHz, CDCl₃) δ 9.71 (d, J = 2.1 Hz, 1H), 9.67 (d, J = 7.6 Hz, 1H), 7.55 – 7.47 (m, 3H), 7.38 (ddd, J = 16.1, 2.2, 1.1 Hz, 1H), 7.22 (dd, J = 16.1, 7.5 Hz, 1H), 7.06 – 6.99 (m, 2H), 3.90 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 194.3, 191.7, 162.4, 155.0, 142.0, 134.2, 132.9 (2C), 132.1, 126.5, 114.8 (2C), MMS (ESL+) m/z calcd for C H O Na [M+ha]¹⁺ 239 0684: found: 239 0682

55.6. **HRMS** (ESI+) m/z calcd. for $C_{13}H_{12}O_3Na[M+Na]^+$: 239.0684; found: 239.0682.

(2*E*,4*E*)-4-(Furan-2-ylmethylene)pent-2-enedial 1e was synthesized following the general procedure and obtained in 56% yield as a pure (*E*)-isomer. ¹H NMR (400 MHz, CDCl₃) δ 9.71 (d, *J* = 7.7 Hz, 1H), 9.69 (d, *J* = 2.3 Hz, 1H), 8.01 (ddd, *J* = 16.1, 2.3, 0.9 Hz, 1H), 7.80 (d, *J* = 1.7 Hz, 1H), 7.32 (dd, *J* = 16.1, 7.7 Hz, 1H), 7.12 (s, 1H), 7.02 (d, *J* = 3.5 Hz, 1H), 6.67 (dd, *J* = 3.6, 1.8 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 194.7, 191.4, 151.0, 148.3, 142.4, 137.5, 133.7, 129.0, 122.3, 113.5. HRMS (ESI+) *m/z* calcd. for C₁₀H₉O₃[M+H]⁺: 177.0546; found: 177.0546.

2.3. Pent-4-ynal 2f



Procedure: To a 250 mL round bottomed flask fitted with a magnetic stir bar, **23** (10.0 mmol, 1 equiv.) was added to CH_2CI_2 (55 mL) followed by Dess-Martin Periodinane (13.0 mmol, 1.3 equiv.). The reaction mixture was stirred at rt. After 20 h, the reaction was complete, as determined by TLC (pentane:Et₂O 7:1). The mixture was diluted with Et₂O (50 mL) and subsequently quenched by addition of a 1:1:1 mixture of sat. aq. $Na_2S_2O_3$ (30 mL), sat. aq. $NaHCO_3$ (30 mL) and H_2O (30 mL), and additional H_2O (50 mL) were added. The phases were separated, and the aqueous phase was extracted with Et₂O (2 x 15 mL). The organic phases were combined and dried over MgSO₄. The crude was concentrated at 50 °C, to remove excess solvents. **2f** was procured in 70% yield as part of a mixture containing 80% compound and 20% CH_2Cl_2 and Et_2O . The characterization of **2f** is known in literature, and corresponds to the obtained product.¹

¹ Y. Yan, J. Chen, L. Zhang, Q. Zheng, Y. Han, H. Zhang, D. Zhang, T. Awakawa, I. Abe and W. Liu, Angew. Chem. Int. Ed. **2013**, 52, 12308.

3. Synthesis of the cyclic oxadendralenic intermediates 3a,b

3.1. Procedure



In a 4 mL glass vial catalyst (*S*)-**A** (0.06 mmol, 0.2 equiv.), aldehyde **2** (0.9 mmol, 1.2 equiv.) and oxadendralenic dienal **1** (0.2 mmol, 1.0 equiv.) were mixed in $CHCl_3$ (0.4 mL). The reaction mixture was heated to 40 °C until completion. Full conversion was determined by ¹H NMR analysis. The crude was loaded directly onto a column and FC (pentane:EtOAc) afforded **3**.

(1*S*,6*S*)-6-Methyl-1,6-dihydro-[1,1'-biphenyl]-2,4-dicarbaldehyde 3a was obtained after 1.5 h following the procedure. FC (pentane:EtOAc 40:1 to 30:1) yielded **3a** as a white solid in 79% yield, >20:1 dr. ¹H NMR (400 MHz, CDCl₃) δ 9.62 (s, 1H), 9.61 (s, 1H), 7.46 – 7.42 (m, 1H), 7.25 – 7.16 (m, 3H), 7.12 – 7.08 (m, 2H), 7.06 (dt, *J* = 5.8, 0.9 Hz, 1H), 4.14 – 4.07 (m,

1H), 2.72 (td, J = 5.8, 1.6 Hz, 1H), 2.02 – 1.85 (m, 1H), 1.02 (d, J = 6.8 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H). ¹³**C NMR** (100 MHz, CDCl₃) δ 192.4, 189.7, 155.3, 142.6, 140.7, 136.5, 134.6, 128.8 (2C), 127.0, 126.7 (2C), 50.6, 37.8, 33.9, 19.4, 19.3. **HRMS** (ESI+) m/z calcd. for C₁₇H₁₈NaO₂ [M+Na]⁺: 277.1119; found: 277.1165.



121.1, 41.7, 38.3, 19.2. **HRMS** (ESI+) *m*/*z* calcd. for C₁₅H₁₄BrO₂ [M+H]⁺: 305.0172; found: 305.0165.

4. Synthesis of the tetrahydroisochromenes 5a-r

4.1. General procedure A

In a 4 mL glass vial catalyst **A** (0.04 mmol, 0.2 equiv.) and pent-2-enedial **1** (0.3 mmol, 1.5 equiv.) were dissolved in CHCl₃ (0.2 mL). Aldehyde **2** (0.2 mmol, 1.0 equiv.) in CHCl₃ (0.2 mL) was added as a stock solution. The reaction mixture was heated to 40 °C for 1.5 h. Afterwards dienophile **4** (1.0 mmol, 5.0 equiv.) and Eu(fod)₃ (0.02 mmol, 0.1 equiv.) were added and the reaction was stirred at 40 °C for the time indicated. Full conversion was determined by a control experiment performed at 0.05 mmol scale of aldehyde from which the reaction progress was monitored by NMR. After full conversion the crude reaction mixture was loaded on a column and purified by FC (pentane:EtOAc) yielding the corresponding product **5**.

4.2. General procedure B

In a 4 mL glass vial catalyst **A** (0.04 mmol, 0.2 equiv.), aldehyde **2** (0.6 mmol, 3.0 equiv.) and pent-2-enedial **1** (0.2 mmol, 1.0 equiv.) were dissolved in CHCl₃ (0.4 mL). The reaction mixture was heated to 40 °C for 1.5 h. Afterwards dienophile **4** (1.0 mmol, 5.0 equiv.) and Eu(fod)₃ (0.02 mmol, 0.1 equiv.) were added and the reaction was stirred at 40 °C for the time indicated. Full conversion was determined by a control experiment performed at 0.05 mmol scale of aldehyde from which the reaction progress was monitored by NMR. After full conversion the crude reaction mixture was loaded on a column and purified by FC (pentane:EtOAc) yielding the corresponding product **5**.

4.3. Results and characterization

Product **5a** was obtained after 24 h following general procedure A. FC (pentane:EtOAc 40:1) afforded the pure compound in 88% yield, >20:1 dr and 99% ee. Yellow oil. $[\alpha]_D^{20} = -95.8 (c=1.0, CH_2Cl_2)$. ¹H NMR (400 MHz, CDCl₃) δ 9.16 (s, 1H), 7.25 – 7.13 (m, 5H), 7.02 – 6.97 (m, 1H), 6.87 (d, *J* = 1.9 Hz, 1H), 5.03 (dd, *J* = 9.9, 2.0 Hz, 1H), 4.03 (dq, *J* = 9.5, 7.1 Hz, 1H), 3.67 (dq, *J* = 9.5, 7.1 Hz, 1H), 3.55 – 3.50 (m, 1H), 2.54 – 2.42 (m, 1H), 2.37 (ddd, *J* = 13.1, 5.4, 2.0 Hz, 1H), 1.91 (pd, *J* = 7.2, 1.5 Hz, 1H), 1.70 – 1.54 (m, 2H), 1.30 (t, *J* = 7.1 Hz, 3H), 0.91 (d, *J* = 7.3 Hz, 3H), 0.81 (d, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 191.4, 147.1, 144.4, 142.8, 138.7, 128.8 (2C), 128.0 (2C), 126.2, 115.0, 101.1, 65.1, 51.4, 43.9, 34.2, 31.9, 27.5, 21.7, 17.1, 15.1. HRMS (ESI+) *m/z* calcd. for C₂₁H₂₇O₃ [M+H]⁺: 327.1955; found: 327.1955. UPC²: IC, CO₂/*i*PrOH 80/20, 3.0 mL·min⁻¹; t_{minor} = 4.0 min; t_{major} = 5.6 min.



Product **5b** was obtained after 24 h following general procedure A. FC (pentane:EtOAc 30:1) afforded the pure compound in 90% yield, >20:1 dr and 99% ee. Yellow oil. $[\alpha]_D^{20}$ = +17.0 (*c*=1, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 9.42 (s, 1H), 7.23 – 7.07 (m, 6H), 6.85 (d, J = 2.1 Hz, 1H), 4.83 (d, J = 5.8 Hz, 1H), 3.98 (d, J = 4.2 Hz, 1H), 3.88 (dq, J = 9.6, 7.1 Hz,

1H), 3.55 (dq, J = 9.6, 7.0 Hz, 1H), 2.22 (dt, J = 6.4, 4.0 Hz, 1H), 2.02 – 1.95 (m, 1H), 1.80 (dtd, J = 11.8, 6.8, 6.2, 2.9 Hz, 2H), 1.21 (t, J = 7.1 Hz, 3H), 0.95 (dd, J = 6.9, 2.8 Hz, 6H), 0.89 (d, J = 6.9 Hz, 3H). ¹³**C NMR** (100 MHz, CDCl₃) δ 191.4, 145.4, 145.3, 144.6, 139.1, 128.2 (4C), 125.9, 116.0, 105.2, 64.6, 48.5, 40.2, 38.3, 35.8, 32.3, 20.4, 19.1, 15.9, 15.0. **HRMS** (ESI+) *m/z* calcd. for C₂₂H₂₈O₃K [M+K]⁺: 379.1670; found: 379.1671. **UPC²**: IC, CO₂/*i*PrOH 90/10, 3.0 mL·min⁻¹; t_{minor} = 5.7 min; t_{major} = 6.7 min.



Product **5c** was obtained after 120 h following general procedure A. FC (pentane:EtOAc 50:1) afforded the pure compound in 74% yield, >20:1 dr and 99% ee. Yellow oil. $[\alpha]_{D}^{20}$ = +30.1 (*c*=0.4, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 9.28 (s, 1H), 7.22 – 7.17 (m, 4H), 7.11 (d, J = 6.0 Hz, 2H), 6.77 (d, J = 2.0 Hz, 1H), 4.99 (d, J = 3.0 Hz, 1H), 3.88 – 3.77 (m, 2H),

3.52 (dq, J = 9.5, 7.0 Hz, 1H), 2.35 (ddd, J = 9.7, 6.9, 2.6 Hz, 1H), 1.96 (dtd, J = 13.6, 6.8, 2.9 Hz, 2H), 1.88 (dt, J = 10.1, 2.6 Hz, 1H), 1.52 – 1.34 (m, 2H), 1.20 (t, J = 7.0 Hz, 3H), 0.97 – 0.90 (m, 7H), 0.84 (d, J = 7.1 Hz, 3H). ¹³**C NMR** (100 MHz, CDCl₃) δ 191.8, 146.0, 145.2, 142.8, 140.1, 128.9 (2C), 127.9 (2C), 125.8, 117.0, 101.8, 64.1, 49.7, 42.0, 40.3, 36.8, 29.1, 24.8, 20.2, 18.9, 15.1, 11.7. **HRMS** (ESI+) *m/z* calcd. for C₂₃H₃₁O₃ [M+H]⁺: 355.2268; found: 355.2266. **UPC**²: IC, CO₂/*i*PrOH 80/20, 3.0 mL·min⁻¹; t_{minor} = 2.4 min; t_{major} = 2.8 min.



Product **5d** was obtained after 24 h following general procedure A. FC (pentane:EtOAc 20:1) afforded the pure compound in 82% yield, >20:1 dr and 99% ee. Yellow oil. $[\alpha]_D^{20} = +19.0 \ (c=1.0, \ CH_2\ Cl_2)$. ¹H NMR (400 MHz, CDCl₃) δ 9.16 (s, 1H), 7.22 (d, *J* = 7.1 Hz, 2H), 7.18 – 7.11 (m, 3H), 6.98 (s, 1H), 6.86 (d, *J* = 1.4 Hz, 1H), 5.01 (dd, *J* = 9.8, 1.9

Hz, 1H), 3.96 (dt, J = 9.5, 6.7 Hz, 1H), 3.58 (dt, J = 9.5, 6.7 Hz, 1H), 3.52 (d, J = 9.7, 1H), 2.51 – 2.41 (m, 1H), 2.35 (ddd, J = 13.1, 5.4, 1.9 Hz, 1H), 1.91 (dsept, J = 7.2 Hz, 1.0 Hz, 1H), 1.69 – 1.56 (m, 4H), 1.47 – 1.37 (m, 2H), 0.95 (d, J = 7.4 Hz, 3H), 0.90 (d, J = 7.3 Hz, 3H), 0.79 (d, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 191.6, 147.3, 144.5, 142.9, 138.6, 128.9 (2C), 128.1 (2C), 126.2, 115.0, 101.3, 69.5, 51.5, 43.9, 34.2, 32.0, 31.7, 27.5, 21.6, 19.2, 17.2, 13.9. HRMS (ESI+) m/z calcd. for C₂₃H₃₁O₃ [M+H]⁺: 355.2268; found: 355.2271. UPC²: IC, CO₂/*i*PrOH 80/20, 3.0 mL·min⁻¹; t_{minor} = 4.0 min; t_{major} = 5.8 min.



Product **5e** was obtained after 22 h following general procedure A. FC (pentane:EtOAc 20:1) afforded the pure compound in 90% yield, >20:1 dr and 99% ee. Yellow oil. $[\alpha]_D^{20} = +2.3$ (*c*=1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 9.16 (s, 1H), 7.31 – 7.19 (m, 2H), 7.19 – 7.11 (m, 3H), 6.98 (s, 1H), 6.86 (d, *J* = 1.1 Hz, 1H), 5.00 (dd, *J* = 9.7, 1.9 Hz,

1H), 3.73 (dd, J = 9.2, 6.6 Hz, 1H), 3.53 (d, J = 9.7 Hz, 1H), 3.33 (d, J = 9.2, 6.8 Hz, 1H), 2.47 (td, J = 11.5, 4.9 Hz, 1H), 2.35 (ddd, J = 13.0, 5.4, 1.8 Hz, 1H), 1.92 (m, 2H), 1.72 – 1.55 (m, 2H), 0.95 (dd, J = 6.7, 1.1 Hz, 6H), 0.91 (d, J = 7.2 Hz, 3H), 0.79 (d, J = 7.2 Hz, 3H). ¹³**C** NMR (100 MHz, CDCl₃) δ 191.4, 147.2, 144.5, 142.8, 138.7, 128.8 (2C), 128.0 (2C), 126.2, 115.0, 101.5, 76.3, 51.5, 43.8, 34.0, 32.0, 28.5, 27.5, 21.5, 19.3, 19.2, 17.3. HRMS (ESI+) m/z calcd. for C₂₃H₃₀O₃Na [M+Na]⁺: 377.2087; found: 377.2085. **UPC**²: IC, CO₂/*i*PrOH 80/20, 3.0 mL·min⁻¹; t_{minor} = 3.6 min; t_{major} = 5.4 min.



Product **5f** was obtained after 24 h following general procedure A. FC (pentane:EtOAc 4:1 to 3:1) afforded the pure compound in 85% yield, >20:1 dr and 99% ee. Yellow oil. $[\alpha]_D^{20} = -76.8 (c=1.0, CH_2Cl_2)$. ¹H NMR (400 MHz, CDCl₃) δ 9.16 (s, 1H), 7.26 – 7.11 (m, 5H), 7.00 – 6.95 (m, 1H), 6.88 – 6.82 (m, 1H), 5.06 (dd, J = 9.8,

2.0 Hz, 1H), 4.03 (qd, J = 7.1, 6.2, 4.3 Hz, 1H), 3.81 (q, J = 3.4 Hz, 3H), 3.58 – 3.48 (m, 1H), 2.55 – 2.37 (m, 2H), 2.13 (s, 1H), 1.98 – 1.86 (m, 1H), 1.73 – 1.54 (m, 2H), 0.90 (d, J = 7.3 Hz, 3H), 0.80 (d, J = 7.1 Hz, 3H). ¹³**C NMR** (100 MHz, CDCl₃) δ 191.4, 146.6, 144.2, 142.3, 138.9, 128.8 (2C), 128.0 (2C), 126.2, 115.1, 101.5, 71.2, 61.8, 51.4, 43.9, 34.0, 31.8, 27.5, 21.7, 17.1. **HRMS** (ESI+) m/z calcd. for C₂₁H₂₇O₄ [M+H]⁺: 343.1904; found: 343.1908. **UPC**²: IC, CO₂/*i*PrOH 60/40, 3.0 mL·min⁻¹; t_{minor} = 3.1 min; t_{major} = 3.9 min.



Product **5g** was obtained after 4 h following general procedure A without using Eu(fod)₃. FC (pentane:EtOAc 20:1) afforded the pure compound in 84% yield, >20:1 dr and 99% ee. Yellow oil. $[\alpha]_D^{20}$ = +100.0 (*c*=1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 9.18 (s, 1H), 7.25 – 7.21 (m, 2H), 7.18 – 7.13 (m, 3H), 6.98 (m, 1H), 6.79 (d, *J* = 1.9 Hz, 1H),

3.55 (d, J = 9.8 Hz, 1H), 3.43 (s, 3H), 3.34 (s, 3H), 2.58 – 2.48 (m, 1H), 2.42 (dd, J = 13.0, 5.6 Hz, 1H), 1.91 (m, 1H), 1.66 – 1.56 (m, 2H), 0.90 (d, J = 7.3 Hz, 3H), 0.82 (d, J = 7.2 Hz, 3H). ¹³**C** NMR (100 MHz, CDCl₃) δ 191.4, 145.2, 144.4, 142.2, 139.3, 128.8 (2C), 128.0 (2C), 126.2, 116.1, 113.5, 50.8, 50.5, 48.9, 43.8, 32.8, 30.6, 27.5, 21.7, 17.2. HRMS (ESI+) m/z calcd. for $C_{21}H_{27}O_4$ [M+H]⁺: 343.1904; found: 343.1903. UPC²: IB, CO₂/MeCN 95/5, 3.0 mL·min⁻¹; t_{minor} = 5.4 min; t_{major} = 6.8 min.



Product **5h** was obtained after 40 h following general procedure A. FC (pentane:EtOAc 25:1) afforded the pure compound in 55% yield, >20:1 dr and 99% ee. Yellow oil. $[\alpha]_D^{20} = -35.6 \ (c=1.0, CH_2Cl_2)$. ¹H NMR (400 MHz, CDCl₃) δ 9.16 (s, 1H), 7.23 (d, *J* = 7.1 Hz, 2H), 7.20 - 7.12 (m, 3H), 6.99 (s, 1H), 6.86 (s, 1H), 3.54 (d, *J* = 9.8 Hz, 1H), 3.43 (s, 3H),

2.41 (dt, J = 11.5, 5.1 Hz, 1H), 2.09 (dd, J = 13.0, 5.4 Hz, 1H), 1.92 (p, J = 7.4 Hz, 1H), 1.77 (t, J = 12.4 Hz, 1H), 1.62 (ddd, J = 11.5, 9.9, 1.5 Hz, 1H), 1.45 (s, 3H), 0.90 (d, J = 7.3 Hz, 3H), 0.82 (d, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 191.3, 147.6, 144.5, 143.0, 138.4, 128.8 (2C), 128.0 (2C), 126.2, 113.7, 102.8, 51.3, 49.6, 44.0, 36.0, 31.3, 27.5, 22.5, 21.8, 17.0. HRMS (ESI+) m/z calcd. for C₂₁H₂₇O₃ [M+H]⁺: 327.1955; found: 327.1959. UPC²: IC, CO₂/*i*PrOH 80/20, 3.0 mL·min⁻¹; t_{minor} = 4.4 min; t_{major} = 6.7 min.

Product **5i** was obtained after 72 h following general procedure A performing the DA reaction at 80 °C. FC (pentane:EtOAc 20:1) afforded the pure compound in 42% yield, >20:1 dr and 99% ee. Yellow oil. $[\alpha]_D^{20} = -142.6$ (*c*=0.8, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 9.15 (s, 1H), 7.25 – 7.21 (m, 2H), 7.21 – 7.13 (m, 3H), 7.01 (s, 1H), 6.84 (d, *J* = 2.1 Hz, 1H),

5.59 (d, *J* = 3.8 Hz, 1H), 4.26 – 4.18 (m, 1H), 4.10 – 4.01 (m, 1H), 3.65 (d, *J* = 9.3 Hz, 1H), 2.85 – 2.74 (m, 1H), 2.69 – 2.57 (m, 1H), 2.10 – 1.92 (m, 2H), 1.91 – 1.69 (m, 2H), 0.98 (d, *J* = 7.2 Hz, 3H), 0.64 (d, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 191.2, 147.0, 144.8, 142.9, 137.9, 128.9 (2C), 128.1 (2C), 126.3, 110.5, 102.0, 68.5, 48.3, 42.2, 41.1, 30.9, 27.8, 22.7, 20.1, 19.1. HRMS (ESI+) *m/z* calcd. for C₂₁H₂₅O₃ [M+H]⁺: 325.1798; found: 325.1806. UPC²: IC, CO₂/*i*PrOH 60/40, 3.0 mL·min⁻¹; t_{major} = 4.5 min; t_{minor} = 5.4 min.



Product **5j** was obtained after 24 h following general procedure B. FC (pentane:EtOAc 80:1 to 40:1) afforded the pure compound in 75% yield, >20:1 dr and 99% ee.

t Yellow oil. $[\alpha]_D^{20} = -36.8$ (*c*=1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 9.36 (s, 1H), 7.25 – 7.04 (m, 11H), 6.83 (d, *J* = 2.0 Hz, 1H), 4.71 (d, *J* = 4.2 Hz, 1H), 3.76 (ddd, *J* = 16.6, 14.2,

6.7 Hz, 2H), 3.42 (dq, *J* = 9.6, 7.0 Hz, 1H), 2.91 – 2.81 (m, 1H), 2.66 – 2.55 (m, 2H), 1.94 (dtd, *J* = 11.4, 7.0, 3.4 Hz, 1H), 1.85 (ddd, *J* = 7.4, 4.8, 2.0 Hz, 1H), 1.12 (t, *J* = 7.1 Hz, 3H), 0.86 (d, *J* = 6.9 Hz, 3H).¹³**C NMR** (100 MHz, CDCl₃) δ 191.6, 145.2, 144.4, 143.5, 140.1, 138.0, 129.4 (2C), 128.4 (2C), 128.2 (2C), 128.1 (2C), 126.1, 125.9, 116.0, 104.2, 64.3, 45.2, 45.0, 39.7, 39.0, 33.8, 16.8, 15.0. **HRMS** (ESI+) *m/z* calcd. for C₂₆H₂₉O₃ [M+H]⁺: 389.2111; found: 389.2115. **UPC²**: IC, CO₂/*i*PrOH 80/20, 3.0 mL·min⁻¹; t_{minor} = 4.9 min; t_{major} = 5.9 min.



Product **5k** was obtained after 24 h following general procedure A. FC (pentane:EtOAc 40:1) afforded the pure compound in 68% yield, >20:1 dr and 95% ee. Yellow oil. $[\alpha]_D^{20}$ = -192.0 (*c*=1.0, CH₂Cl₂). ¹**H NMR** (400 MHz, CDCl₃) δ 9.34 (s, 1H), 7.37 – 7.28 (m, 2H), 7.28 – 7.17 (m, 4H), 6.86 (s, 1H), 4.80 (d, *J* = 4.6 Hz, 1H), 3.91 (dq, *J* = 9.6, 7.0 Hz, 1H), 3.61

(dq, *J* = 9.6, 7.0 Hz, 1H), 3.38 (d, *J* = 9.6, 1H), 2.15 (qt, *J* = 6.9, 4.4 Hz, 1H), 2.00 – 1.86 (m, 1H), 1.77 (dd, *J* = 11.6, 4.3 Hz, 1H), 1.26 (t, *J* = 7.1 Hz, 3H), 1.19 (d, *J* = 6.9 Hz, 3H), 1.02 (d, *J* = 6.5 Hz, 3H). ¹³**C** NMR (100 MHz, CDCl₃) δ 191.9, 145.0, 144.0, 143.9, 138.7, 128.5 (2C), 128.1 (2C), 126.1, 116.3, 103.1, 64.4, 50.1, 42.4, 42.3, 33.7, 18.6, 16.8, 15.1. HRMS (ESI+) *m/z* calcd. for C₂₀H₂₅O₃ [M+H]⁺: 313.1798; found: 313.1799. **UPC**²: IC, CO₂/*i*PrOH 80/20, 3.0 mL·min⁻¹; t_{major} = 3.6 min; t_{minor} = 5.0 min.

Product **5I** was obtained after 24 h following general procedure A. FC (pentane:EtOAc 80:1) afforded the pure compound in 79% yield, >20:1 dr and 99% ee. Yellow oil. $[\alpha]_{D}^{20} = -138.0 \ (c=1.0, CH_2Cl_2)$. ¹H NMR (400 MHz, CDCl₃) δ 9.29 (s, 1H), 7.25 – 7.12 (m, 6H), 6.80 – 6.75 (m, 1H), 4.82 (d, J = 3.1 Hz, 1H), 3.77 (dq, J = 9.6, 7.1 Hz, 1H), 3.66 (d, J = 9.2 Hz,

1H), 3.49 (dq, J = 9.6, 7.0 Hz, 1H), 2.10 (dtt, J = 16.5, 8.4, 4.1 Hz, 2H), 1.80 (dt, J = 11.1, 2.4 Hz, 1H), 1.54 – 1.44 (m, 1H), 1.44 – 1.33 (m, 1H), 1.33 – 1.26 (m, 1H), 1.22 (ddt, J = 13.6, 6.6, 3.3 Hz, 3H), 1.15 (t, J = 7.1 Hz, 3H), 1.05 (d, J = 7.1 Hz, 3H), 0.85 (t, J = 7.2 Hz, 3H). ¹³**C** NMR (100 MHz, CDCl₃) δ 192.1, 145.3, 144.3, 143.2, 139.1, 128.3 (2C), 128.0 (2C), 126.0, 116.7, 102.9, 64.0, 45.6, 44.9, 39.0, 32.6, 28.5, 26.6, 23.0, 18.1, 15.1, 14.0.HRMS (ESI+) m/z calcd. for C₂₃H₃₀O₃Na [M+Na]⁺: 377.2087; found: 377.2081. UPC²: IC, CO₂/*i*PrOH 80/20, 3.0 mL·min⁻¹; t_{minor} = 3.0 min; t_{major} = 3.8 min.



≟ Ĥ ≟ *n*Bu Me

Product **5m** was obtained after 24 h following general procedure B, performing the first step at rt. FC (pentane:EtOAc 40:1 to 30:1) afforded the pure compound in 77% yield, >20:1 dr and 96% ee. Yellow oil. $[\alpha]_D^{20} = -52.2$ (*c*=1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 9.33 (s, 1H), 7.25 – 7.23 (m, 1H), 7.21 – 7.13 (m, 3H), 7.08 – 7.01 (m, 3H), 6.94 – 6.85

(m, 3H), 6.79 - 6.73 (m, 2H), 4.68 (d, J = 3.9 Hz, 1H), 3.86 (d, J = 9.5 Hz, 1H), 3.81 (dq, J = 9.4, 7.4 Hz, 1H), 3.47 (dq, J = 9.5, 7.0 Hz, 1H), 2.91 (dd, J = 12.2, 10.2 Hz, 1H), 2.28 (d, J = 12.1, 1H), 1.69 (qt, J = 7.1, 3.8 Hz, 1H), 1.19 (t, J = 7.0 Hz, 3H), 0.68 (d, J = 7.0 Hz, 3H). 13 **C NMR** (100 MHz, CDCl₃) δ 191.5, 145.0, 144.4, 142.9, 141.8, 138.7, 128.7 (2C), 128.2 (2C), 127.8 (2C), 127.7 (2C), 126.5, 125.8, 116.0, 103.1, 64.3, 55.6, 50.0, 40.9, 34.1, 17.7, 15.1. HRMS (ESI+) m/z calcd. for $C_{25}H_{27}O_3$ [M+H]⁺: 375.1955; found: 375.1958. UPC²: IC, CO₂/*i*PrOH 80/20, 3.0 mL·min⁻¹; t_{major} = 4.3 min; t_{minor} = 6.4 min.



Product **5n** was obtained after 24 h following general procedure B. FC (pentane:EtOAc 50:1) afforded the pure compound in 47% yield, 17:1 dr and 96% ee. Yellow oil. $[\alpha]_D^{20} = -155.6 \ (c=1.0, CH_2Cl_2)$. ¹H NMR (400 MHz, CDCl₃) δ 9.28 (s, 1H), 7.30 – 7.13 (m, 6H), 6.80 (s, 1H), 4.82 (d, J = 2.9 Hz, 1H), 3.84 (d, J = 9.9 Hz, 1H), 3.77 (m, 1H), 3.56 – 3.45 (m, 1H), 2.40 (dt, J = 17.6, 3.4 Hz, 1H), 2.21 – 1.95 (m, 5H), 1.15 (m, 6H). ¹³C NMR (100 MHz,

CDCl₃) δ 191.7, 145.1, 143.6, 143.3, 138.7, 128.3 (2C), 128.2 (2C), 126.3, 116.0, 102.4, 81.0, 71.1, 64.1, 45.7, 44.9, 38.0, 32.7, 18.3, 18.1, 15.1. **HRMS** (ESI+) *m/z* calcd. for C₂₂H₂₅O₃ [M+H]⁺: 337.1798; found: 337.1803. **UPC²**: IC, CO₂/*i*PrOH 80/20, 3.0 mL·min⁻¹; t_{major} = 2.9 min; t_{minor} = 3.3 min.



Product **50** was obtained after 24 h following general procedure A. FC (pentane:EtOAc 50:1) afforded the pure compound in 65% yield, >20:1 dr and 98% ee. Yellow oil. $[\alpha]_D^{20} = 63.2$ (*c*=1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 9.34 (s, 1H), 7.26 (s, 1H), 7.23 (dt, *J* = 6.7, 2.0 Hz, 1H), 7.17 (s, 1H), 7.10 – 7.02 (m, 2H),

6.85 (d, J = 2.0 Hz, 1H), 4.83 (d, J = 5.1 Hz, 1H), 3.91 – 3.81 (m, 2H), 3.54 (dq, J = 9.6, 7.1 Hz, 1H), 2.20 – 2.16 (m, 1H), 1.93 (td, J = 6.7, 2.0 Hz, 1H), 1.88 – 1.79 (m,2H), 1.21 (t, J = 7.1 Hz, 3H), 0.96 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 7.0 Hz, 3H), 0.88 (d, J = 7.0 Hz, 3H). ¹³**C** NMR (100 MHz, CDCl₃) δ 191.1, 148.0, 145.8, 144.7, 138.5, 131.2, 129.6, 129.1, 127.2, 122.2, 115.7, 104.7, 64.5, 48.8, 40.3, 38.1, 35.3, 31.6, 20.3, 19.1, 16.2, 15.1. HRMS (ESI+) m/z calcd. for C₂₂H₂₈BrO₃ [M+H]⁺: 419.1216; found: 419.1215. UPC²: IC, CO₂/*i*PrOH 80/20, 3.0 mL·min⁻¹; t_{major} = 2.5 min; t_{minor} = 2.9 min.



Product **5p** was obtained after 22 h following general procedure B. FC (pentane:EtOAc 60:1) afforded the pure compound in 88% yield, >20:1 dr and 99% ee. Yellow oil. $[\alpha]_D^{20}$ = 89.0 (*c*=1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 9.36 (s, 1H), 7.32 (s, 1H), 7.30 (s, 1H), 7.16 (s, 1H), 7.03 (s, 1H), 7.02 (s, 1H), 6.84 (d, *J* = 2.1 Hz,

1H), 4.83 (d, J = 5.2 Hz, 1H), 3.92 – 3.82 (m, 2H), 3.54 (dq, J = 9.5, 7.0 Hz, 1H), 2.18 – 2.15 (m, 1H), 1.97 – 1.75 (m, 3H), 1.21 (t, J = 7.1 Hz, 3H), 0.96 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 6.9 Hz, 3H), 0.87 (d, J = 7.0 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 191.1, 145.7, 144.7, 144.6, 138.9, 131.2 (2C), 130.1 (2C), 119.7, 115.8, 104.8, 64.6, 48.8, 40.1, 38.2, 35.4, 31.8, 20.3, 19.1, 16.2, 15.1. HRMS (ESI+) m/z calcd. for C₂₂H₂₈BrO₃ [M+H]⁺: 419.1216; found: 419.1216. UPC²: IC, CO₂/*i*PrOH 80/20, 3.0 mL·min⁻¹; t_{major} = 2.9 min; t_{minor} = 3.5 min.



Product **5q** was obtained after 72 h following general procedure B. FC (pentane:EtOAc 30:1) afforded the pure compound in 71% yield, >20:1 dr and 99% ee. Yellow oil. $[\alpha]_D^{20}$ = 45.6 (*c*=1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 9.34 (s, 1H), 7.13 (s, 1H), 7.03 (s, 1H), 7.02 (s, 1H), 6.82 (d, *J* = 2.1 Hz, 1H), 6.74 (s, 1H),

6.72 (s, 1H), 4.81 (d, J = 5.8 Hz, 1H), 3.92 – 3.83 (m, 2H), 3.74 (s, 3H), 3.54 (dq, J = 9.6, 7.1 Hz, 1H), 2.15 (dt, J = 6.4, 4.0 Hz, 1H), 1.95 (td, J = 6.9, 2.2 Hz, 1H), 1.84 – 1.73 (m, 2H), 1.21 (t, J = 7.1 Hz, 3H), 0.93 (dd, J = 6.9, 4.9 Hz, 6H), 0.86 (d, J = 6.9 Hz, 3H). ¹³**C NMR** (100 MHz, CDCl₃) δ 191.4, 157.7, 145.2, 144.5, 139.4, 137.4, 129.0 (2C), 116.0, 113.6 (2C), 105.2, 64.7, 55.1, 48.5, 39.3, 38.3, 35.7, 32.3, 20.4, 19.1, 15.9, 15.1. **HRMS** (ESI+) m/z calcd. for C₂₃H₃₁O₄ [M+H]⁺: 371.2217; found: 371.2220. **UPC**²: IC, CO₂/*i*PrOH 80/20, 3.0 mL·min⁻¹; t_{minor} = 3.7 min; t_{major} = 5.0 min.



Product **5r** was obtained after 24 h following general procedure B. FC (pentane:EtOAc 40:1) afforded the pure compound in 65% yield, >20:1 dr and 99% ee. Yellow oil. $[\alpha]_D^{20} = -146.6$ (*c*=1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 9.48 (s, 1H), 7.24 (dd, *J* = 1.9, 0.9 Hz, 1H), 7.16 (s, 1H), 6.82 (d, *J* = 2.2 Hz, 1H), 6.17 (dd, *J* = 3.2, 1.9 Hz, 1H), 5.74

(dt, *J* = 3.2, 0.9 Hz, 1H), 4.80 (d, *J* = 7.3 Hz, 1H), 4.15 (d, *J* = 3.3 Hz, 1H), 3.88 (dq, *J* = 9.6, 7.1 Hz, 1H), 3.55 (dq, *J* = 9.6, 7.1 Hz, 1H), 2.32 (dt, *J* = 5.3, 3.5 Hz, 1H), 2.05 (td, *J* = 9.5, 2.6 Hz, 1H), 1.69 −1.61 (m, 1H), 1.44 (dq, *J* = 9.8, 6.8 Hz, 1H), 1.21 (t, *J* = 7.1 Hz, 3H), 0.97 (d, *J* = 6.7 Hz, 3H), 0.93 (d, *J* = 6.8 Hz, 3H), 0.88 (d, *J* = 6.9 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 190.9, 156.2, 146.5, 146.4, 140.9, 135.5, 115.5, 110.3, 106.8, 105.6, 64.9, 43.4, 37.8, 36.2, 33.2, 32.6, 20.6, 19.6, 15.0 (2C). HRMS (ESI+) *m/z* calcd. for C₂₀H₂₆O₄Na [M+Na]⁺: 353.1723; found: 353.1722. UPC²: IA, Gradient CO₂/*i*PrOH, first 99/1 in 0.5 min, then 99/1 → 60/40 (10%/min), 3.0 mL·min⁻¹; t_{major} = 2.7 min; t_{minor} = 2.8 min.

5. Synthesis of the tetrahydroisochromenes 6a-e

5.1. General Procedure C

In a 4 mL glass vial catalyst (*S*)-**A** (0.04 mmol, 0.2 equiv.) and (2*E*)-4-benzylidenepent-2-enedial **1a** (0.2 mmol, 1.0 equiv.) were dissolved in CHCl₃ (0.4 mL), followed by the addition of aldehyde **2** (0.6 mmol, 5.0 equiv.). The reaction mixture was heated to 40 °C until full conversion of **1a** into intermediate. Full conversion was determined by a control experiment performed at 0.05 mmol scale, from which the reaction progress was monitored by NMR. Next, catalyst (*R*)-**A** (0.04 mmol, 0.2 equiv.) was added and the reaction was set at rt until full conversion into the desired product was reached. Then the crude reaction mixture was loaded on a column and purified by FC (EtOAc/pentane) yielding the corresponding product **6**.

5.2. Results and characterization



Product **6a** was obtained after 24 h following procedure C, employing 3.0 equiv. of aldehyde **2**, without adding the other enantiomer of the catalyst and running the second
 Step at 40 °C. FC (pentane:EtOAc 5:1) afforded the pure compound in 73% yield, 7:1 dr and 99% ee. Yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 9.22 (s, 1H⁺), 7.31 – 7.05 (m, 6H⁺),

6.82 (d, $J = 2.1 \text{ Hz}, 1\text{ H}^*$), 6.75 (d, J = 2.2 Hz, 1 H), 5.36 (d, $J = 1.8 \text{ Hz}, 1\text{ H}^*$), 5.32 (s, 1H), 3.32 – 3.25(m, 1H), 3.25 – 3.21 (m, 1H*), 2.50 (ddd, J = 12.3, 5.4, 2.2 Hz, 1H), 2.40 (ddd, J = 11.7, 4.7 Hz, 1.8 Hz, 1H*), 2.37 – 2.28 (m, 1H*), 2.27 – 2.19 (m, 1H), 1.64 – 1.51 (m, 1H*), 0.90 – 0.81 (m, 6H*). ¹³C NMR (100 MHz, CDCl₃) δ 191.8⁺, 145.2⁺, 145.1⁺, 143.7, 143.5*, 137.3⁺, 128.5*, 128.4*, 128.2, 128.1 (2C*), 128.1, 126.2*, 126.1, 113.1, 112.5*, 98.3*, 97.3, 48.3, 48.0*, 40.4*, 37.5*, 36.7, 33.1, 32.5*, 30.9, 15.4*, 15.3, 9.9, 3.8*.**HRMS** (ESI+) m/z calcd. for C₁₈H₂₀O₃Na [M+Na]⁺: 307.1305; found: 307.1307. **UPC**²: IA, Gradient CO₂/MeOH, first 99/1 in 0.5 min, then 99/1 \rightarrow 60/40 (10%/min), 3.0 mL·min⁻¹; t_{major} = 4.6 min; t_{minor} = 4.1 min.



Product **6b** was obtained after 24 h following general procedure C with some modifications. In the first step, 1.2 equiv. of **1a** was used along with 1 equiv. of propionaldehyde **2c** (added by weight). After 3 h, acetaldehyde **2g** (5.0 equiv.) was added

Me⁻ as part of the second step, and the reaction was stirred at 40 °C. Furthermore, there were no addition of the other enantiomer of the catalyst. FC (pentane:EtOAc 6:1) afforded the pure compound in 60% yield, 2:1 dr and 99% ee. Yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 9.21 (s, 1H⁺), 7.30 – 7.03 (m, 6H⁺), 6.84 (d, J = 1.0 Hz, 1H⁺), 6.79 (d, J = 2.0 Hz, 1H), 5.61 (s, 1H), 5.33 (dd, J = 10.2, 3.7 Hz, 1H⁺), 3.83 – 3.73 (m, 1H⁺), 3.58 – 3.50 (m, 1H), 3.28 (d, J = 10.0 Hz, 1H), 3.23 (d, J = 10.1 Hz, 1H⁺), 2.43 – 2.18 (m, 2H⁺), 1.50 – 1.34 (m, 2H⁺), 0.92 – 0.85 (m, 3H⁺). ¹³C NMR (100 MHz, CDCl₃) δ 191.8, 191.6⁺, 147.2⁺, 145.6, 144.2, 143.8⁺, 143.7, 143.4⁺, 137.8⁺, 128.3 (2C⁺), 128.2 (2C⁺), 128.1 (2C), 126.2⁺, 115.3, 114.3⁺, 96.0⁺, 92.4, 48.3, 48.2⁺, 42.3⁺, 41.7, 35.8⁺, 34.4⁺, 31.1, 29.6, 16.0⁺, 15.9. HRMS (ESI+) *m/z* calcd. for C₁₇H₁₉O₃ [M+H]⁺: 271.1329; found: 271.1326. UPC²: IA, Gradient CO₂/MeOH, first 99/1 in 0.5 min, then 99/1 → 60/40 (10%/min), 3.0 mL·min⁻¹; t_{maior} = 4.5 min; t_{minor} = 4.2 min.



Product **6c** was obtained after 36 h following general procedure C. FC (pentane:EtOAc 6:1) afforded the pure compound in 49% yield, >20:1 dr and 99% ee. Yellow solid. $[\alpha]_D^{20} = +86.6 \ (c=1.0, CH_2Cl_2)$. ¹H NMR (400 MHz, CDCl₃) δ 9.21 (s, 1H), 7.32 (ddd, *J* = 14.9, 8.3, 6.7 Hz, 4H), 7.25 - 7.10 (m, 7H), 7.09 - 7.00 (m, 3H), 6.84 (d, *J* = 2.3 Hz, 1H), 6.73 -

6.65 (m, 2H), 4.99 (s, 1H), 3.53 (d, J = 10.2, 1H), 3.15 – 3.05 (m, 2H), 2.97 (ddd, J = 12.4, 4.4, 2.2 Hz, 1H), 2.56 (dd, J = 14.7, 6.6 Hz, 1H), 2.48 – 2.38 (m, 2H), 2.33 – 2.22 (m, 1H), 2.17 (t, J = 13.8 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 191.5, 145.7, 143.8 (2C), 143.6, 140.3, 138.5, 137.2, 129.3 (2C), 129.2 (3C), 128.5 (2C), 128.4 (2C), 128.2 (2C), 126.5, 126.2, 126.2, 113.4, 93.6, 45.8, 42.0, 37.6, 37.2, 33.0, 30.6. HRMS (ESI+) m/z calcd. for C₃₀H₂₈O₃Na [M+Na]⁺: 359.1931; found: 359.1934. UPC²: IA, Gradient CO₂/MeOH, first 99/1 in 0.5 min, then 99/1 → 60/40 (10%/min), 3.0 mL·min⁻¹; t_{major} = 6.3 min; t_{minor} = 5.5 min.



Product **6d** was obtained after 72 h following general procedure C. FC (pentane:EtOAc 5:1) afforded the pure compound in 45% yield, >20:1 dr and 99% ee. Yellow solid. $[\alpha]_D^{20} = +32.8$ (*c*=1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 9.21 (s, 1H), 7.33 – 7.08 (m, 5H), 7.02 (d, *J* = 2.0 Hz, 1H), 6.74 (d, *J* = 2.3 Hz, 1H), 5.57 – 5.53 (d, 1.5 Hz, 1H), 3.62 (d, *J* =

10.3 Hz, 1H), 3.34 (bs, 1H), 2.78 (ddd, J = 12.8, 5.3, 2.3 Hz, 1H), 2.02 – 1.91 (m, 1H), 1.79 – 1.67 (m, 1H), 1.49 – 1.10 (m, 12H), 0.88 (dt, J = 10.3, 6.8 Hz, 6H). ¹³**C NMR** (100 MHz, CDCl₃) δ 191.6, 145.0, 144.3, 143.9, 138.0, 128.2 (4C), 126.1, 114.4, 94.2, 43.7, 40.0, 35.5, 29.4, 28.9, 25.9, 24.9, 23.6, 23.3, 22.9, 14.0, 14.0. **HRMS** (ESI+) m/z calcd. for C₂₄H₃₂O₃Na [M+Na]⁺: 391.2244; found: 391.2244. **UPC**²: IA, Gradient CO₂/MeOH, first 99/1 in 0.5 min, then 99/1 \rightarrow 60/40 (10%/min), 3.0 mL·min⁻¹; t_{major} = 4.3 min; t_{minor} = 4.1 min.



Product **6e** was obtained after 48 h following general procedure C. FC (pentane:EtOAc 5:1) afforded the pure compound in 47% yield, >20:1 dr and 99% ee. Yellow solid. $[\alpha]_D^{20}$ = +78.2 (*c*=1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 9.22 (s, 1H), 7.28 (d, *J* = 7.4 Hz, 2H), 7.22 - 7.10 (m, 3H), 7.05 - 6.98 (m, 1H), 6.75 (d, *J* = 2.3 Hz, 1H), 5.60 - 5.54 (m, 1H), 3.62

(d, J = 10.8, 1H), 3.16 (d, J = 3.9 Hz, 1H), 2.85 – 2.74 (m, 1H), 1.94 – 1.85 (m, 1H), 1.74 (tt, J = 10.5, 3.7 Hz, 1H), 1.48 – 1.38 (m, 1H), 1.37 – 1.09 (m, 3H), 0.97 (t, J = 7.5 Hz, 3H), 0.88 (t, J = 7.5 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 191.7, 145.2, 144.3, 143.8, 137.9, 128.2 (4C), 126.1, 114.3, 93.9, 42.8, 40.2, 37.1, 28.3, 18.4, 16.8, 11.7, 7.0. HRMS (ESI+) m/z calcd. for $C_{20}H_{24}O_3Na$ [M+Na]⁺: 335.1618; found: 335.1618. UPC²: IA, Gradient CO₂/MeOH, first 99/1 in 0.5 min, then 99/1 \rightarrow 60/40 (10%/min), 3.0 mL·min⁻¹; t_{major} = 4.1 min; t_{minor} = 3.9 min.

6. Transformations

6.1. Synthesis of (*R*)-4,5-Dimethyl-3-oxo-6-phenyl-4,4a,5,6-tetrahydro-3H-4 λ^3 ,5 λ^3 ,6 λ^3 -isochromene-7-carbaldehyde 7



Procedure: A flame dried 25 mL flask was charged with **6a** (0.2 mmol, 1.0 equiv.) and a magnetic stir bar, followed by the addition of NaHCO₃ (7.2 mmol, 36.0 equiv.) and CH_2CI_2 (10 mL). Next, DMP was added and the flask was fitted with a septum and flushed with N₂. The reaction was set to react at rt. Upon full conversion (TLC, pentane:EtOAc 4:1), Et₂O (5 mL) was added to the reaction and the mixture was filtered and concentrated *in vacuo*. The crude was purified by FC (pentane:EtOAc 5:1) yielding the oxidized product **7** in 38% yield and >20:1 dr.

¹H NMR (400 MHz, CDCl₃) δ 9.27 (s, 1H), 7.31 (td, *J* = 7.4, 7.0, 1.2 Hz, 2H), 7.26 – 7.21 (m, 1H), 7.17 – 7.07 (m, 3H), 7.0 (d, *J* = 2.9 Hz, 1H), 3.30 – 3.22 (m, 1H), 3.09 (qd, *J* = 7.2, 5.3 Hz, 1H), 2.66 (ddd, *J* = 11.9, 5.5, 2.8 Hz, 1H), 1.73 (ddq, *J* = 12.9, 10.1, 6.5 Hz, 1H), 1.20 (d, *J* = 7.3 Hz, 3H), 0.86 (d, *J* = 6.4 Hz, 3H).¹³C NMR (100 MHz, CDCl₃) δ 191.1, 170.6, 142.5,

142.2, 140.8, 138.9, 128.5 (4C), 126.8, 115.5, 47.6, 38.1, 36.5, 35.2, 15.1, 10.1. **HRMS** (ESI+) *m/z* calcd. for C₁₈H₁₉O₃Na [M+H]⁺: 283.1329; found: 283.1329.

6.2. Synthesis of (*R*)-3-Ethoxy-4,5-dimethyl-6-phenyl-4,4a,5,6-tetrahydro-3H- $3\lambda^3$, $4\lambda^3$, $5\lambda^3$, $6\lambda^3$ -isochromene-7-carbaldehyde 8



Procedure: In a 12 mL glass vial, **6a** (0.91 mmol, 1.0 equiv.) was dissolved in pyridine (1.8 mL). The solution was cooled to 0 °C after which Ac₂O (18.2 mmol, 20 equiv.) was added. Following the addition of DMAP (0.27 mmol, 0.3 equiv), the reaction mixture was set at rt and left to react overnight. By means of a TLC analysis (pentane:EtOAc 4:1), full conversion into the acetylated reaction intermediate was achieved after 20 h. The crude was plugged through silica (pentane:EtOAc 9:1 \rightarrow 3:1), affording the intermediate nearly clean as a yellow oil.

Next, the intermediate (0.6 mmol, 1.0 equiv.) was dissolved in $CHCl_3$ (1.4 mL) followed by the addition of EtOH (6.0 mmol, 10 equiv.). The reaction mixture was cooled to 0 °C, and then TMSOTF (0.6 mmol, 1.0 equiv.) was added. After 5 h at 0 °C, the reaction was allowed to heat to rt and stirred overnight. Full conversion was achieved after 24 h, as found by TLC analysis (pentane:EtOAc 4:1). The crude was loaded

directly on a column, and purified by FC (pentane:EtOAc 20:1 \rightarrow 10:1) yielding **8** as a yellow oil, in 7:1 dr and 57% yield over two steps.



Only signals of the major diastereoisomer is reported: ¹H NMR (400 MHz, CDCl₃) δ 9.21 (s, 1H), 7.31 – 7.09 (m, 5H), 7.06 (d, *J* = 1.9 Hz, 1H), 6.73 (d, *J* = 2.3 Hz, 1H), 4.94 (d, *J* = 1.8 Hz, 1H), 3.85 (dq, *J* = 9.8, 7.1 Hz, 1H), 3.64 (dq, *J* = 9.8, 7.1 Hz, 1H), 3.30 – 3.24 (m, 1H), 2.47 (ddd, *J* = 12.2, 5.4, 2.2 Hz, 1H), 2.20 (qdd, *J* = 7.2, 5.3, 1.9 Hz, 1H), 1.55 (ddq, *J* =

12.9, 9.9, 6.5 Hz, 1H), 1.23 (t, J = 7.1 Hz, 3H), 0.85 (d, J = 1.0 Hz, 3H), 0.84 (d, J = 1.7 Hz, 3H). ¹³**C NMR** (100 MHz, CDCl₃) δ 191.5, 145.1, 145.0, 143.9, 137.3, 128.1 (4C), 126.1, 113.6, 102.9, 64.2, 48.3, 36.8, 33.9, 30.9, 15.3, 15.1, 10.0. **HRMS** (ESI+) m/z calcd. for C₂₀H₂₄O₃Na [M+Na]⁺: 335.1618; found: 335.1622.

7. X-Ray structures

7.1. Oxadendralenic dienal 1a

ltem	Value
Molecular formula	$C_{12}H_{10}O_2$
Formula weight	186.2
Crystal system	orthorhombic
Space Group	P 2 ₁ 2 ₁ 2 ₁
a (Å)	7.0175
b (Å)	11.1406
c (Å)	11.9874
α (°)	90
β (°)	90
γ (°)	90
Volume (Å ³)	937.18
Z	4
Т (К)	110
ρ (g cm ⁻¹)	1.32
λ (Å)	0.71073
μ (mm⁻¹)	0.089
# measured refl	7396
# unique refl	2232
R _{int}	0.0635
# parameters	127
R(F ²), all refl	0.076
R _w (F ²), all refl	0.1312
Goodness of fit	1.067



Crystal data for [**1a**]: $C_{12}H_{10}O_2$, M = 186.2, orthorhombic, space group P $2_12_12_1$ (no. 115), a = 7.0175(4) Å, b = 11.1406(6) Å, c = 11.9874(6) Å, Flack parameter = -0.5, V = 937.18(8) Å³, T = 110 K, Z = 4, $d_c = 1.32$ g cm⁻³, μ (Mo K α , $\lambda = 0.71073$ Å) = 0.089 mm⁻¹, 7396 reflections collected, 2232 unique [$R_{int} = 0.0635$], which were used in all calculations. Refinement on F², final R(F) = 0.076, $R_w(F^2) = 0.1312$. CCDC number 1419567.

7.2. Intermediate 3b

ltem	Value
Molecular formula	$C_{15}H_{13}BrO_2$
Formula weight	305.16
Crystal system	orthorhombic
Space Group	P 2 ₁ 2 ₁ 2 ₁
a (Å)	6.1506
b (Å)	7.564
c (Å)	28.362
α (°)	90
β (°)	90
γ (°)	90
Volume (Å ³)	1319.5
Z	4
Т (К)	100
ρ (g cm ⁻¹)	1.536
λ (Å)	0.56086
μ (mm⁻¹)	1.669
# measured refl	5932
# unique refl	1902
R _{int}	0.071
# parameters	164
R(F ²), all refl	0.047
R _w (F ²), all refl	0.0739
Goodness of fit	1.003



Crystal data for **[3b]**: $C_{15}H_{13}BrO_2$, M = 305.16, orthorhombic, space group P $2_12_12_1$ (no. 115), a = 6.1506(18)Å, b = 7.564(2) Å, c = 28.362(8) Å, Flack parameter = 0.01, V = 1319.5(6) Å³, T = 100 K, Z = 4, $d_c = 1.536$ g cm⁻³, μ (Mo K α , $\lambda = 0.56086$ Å) = 1.669 mm⁻¹, 5932 reflections collected, 1902 unique [$R_{int} = 0.071$], which were used in all calculations. Refinement on F², final R(F) = 0.047, $R_w(F^2) = 0.0739$. CCDC number 1408759.

7.3. Tetrahydroisochromene 5b

ltem	Value
Molecular formula	$C_{22}H_{28}O_3$
Formula weight	340.47
Crystal system	orthorhombic
Space Group	P 2 ₁ 2 ₁ 2 ₁
a (Å)	7.5376
b (Å)	10.5784
c (Å)	23.8774
α (°)	90
β (°)	90
γ (°)	90
Volume (ų)	1903.9
Z	4
Т (К)	100
ρ (g cm ⁻¹)	1.1877
λ (Å)	0.71073
μ (mm⁻¹)	0.077
# measured refl	7273
# unique refl	3091
R _{int}	0.0793
# parameters	229
R(F ²), all refl	0.1427
R _w (F ²), all refl	0.13
Goodness of fit	1.0032



Crystal data for [**5b**]: $C_{22}H_{28}O_3$, M = 340.47, orthorhombic, space group P $2_1 2_1 2_1$ (no. 115), a = 7.5376(6)Å, b = 10.5784(10) Å, c = 23.8774(19) Å, V = 1903.9(3) Å³, T = 100 K, Z = 4, $d_c = 1.1877$ g cm⁻³, μ (Mo K α , $\lambda = 0.71073$ Å) = 0.077 mm⁻¹, 7273 reflections collected, 3091 unique [$R_{int} = 0.0793$], which were used in all calculations. Refinement on F², final R(F) = 0.1427, $R_w(F^2) = 0.13$. CCDC number 1405309.

7.4. Tetrahydroisochromene 5i

ltem	Value
Molecular formula	$C_{21}H_{24}O_3$
Formula weight	324.4
Crystal system	monoclinic
Space Group	P 2 ₁
a (Å)	8.8945
b (Å)	21.16
c (Å)	9.0481
α (°)	90
β (°)	91.63
γ (°)	90
Volume (ų)	1702.24
Z	4
Т (К)	100
ρ (g cm ⁻¹)	1.266
λ (Å)	0.71073
μ (mm ⁻¹)	0.083
# measured refl	11096
# unique refl	5072
R _{int}	0.0268
# parameters	437
R(F ²), all refl	0.0451
R _w (F ²), all refl	0.0847
Goodness of fit	1.074



Crystal data for [**5i**]: C₂₁H₂₄O₃, *M* = 324.4, monoclinic, space group P 2₁ (no. 6), *a* = 8.8945(2) Å, *b* = 21.16(5) Å, *c* = 9.0481(2) Å, *b* = 91.63(19)°, *V* = 1702.24(7) Å³, *T*= 100 K, *Z* = 4, d_c = 1.266 g cm⁻³, μ (Mo Kα, λ = 0.71073 Å) = 0.083 mm⁻¹, 11096 reflections collected, 5072 unique [R_{int} = 0.0268], which were used in all calculations. Refinement on F², final R(F) = 0.0451, R_w(F²) = 0.0847. CCDC number 1405275.

7.5. Tetrahydroisochromene 6a

lk e ue	Value
item	value
Molecular formula	$C_{18}H_{20}O_3$
Formula weight	284.36
Crystal system	monoclinic
Space Group	P 2 ₁
a (Å)	7.503
b (Å)	10.304
c (Å)	10.253
α (°)	90
β (°)	92.82
γ (°)	90
Volume (Å ³)	791.7
Z	2
Т (К)	293
ρ (g cm ⁻¹)	1.1928
λ (Å)	0.71073
μ (mm⁻¹)	0.08
# measured refl	5304
# unique refl	2910
R _{int}	0.1847
# parameters	192
R(F ²), all refl	0.2768
R _w (F ²), all refl	0.3441
Goodness of fit	0.959



Crystal data for [**6a**]: $C_{18}H_{20}O_3$, M = 284.36, monoclinic, space group P 2_1 (no. 6), a = 7.503(3) Å, b = 10.304(5) Å, c = 10.253(5) Å, $\delta = 92.82(4)^\circ$, Flack parameter = -3.6, V = 791.7(6) Å³, T = 293 K, Z = 2, $d_c = 1.1928$ g cm⁻³, μ (Mo K α , $\lambda = 0.71073$ Å) = 0.08 mm⁻¹, 5304 reflections collected, 2910 unique [$R_{int} = 0.1847$], which were used in all calculations. Refinement on F², final R(F) = 0.2768, $R_w(F^2) = 0.3441$. CCDC number 1405277.

7.6. Tetrahydroisochromene 6e

ltem	Value
Molecular formula	$C_{20}H_{24}O_3$
Formula weight	312.41
Crystal system	orthorhombic
Space Group	P 2 ₁ 2 ₁ 2 ₁
a (Å)	8.6911
b (Å)	9.1112
c (Å)	21.5901
α (°)	90
β (°)	90
γ (°)	90
Volume (Å ³)	1709.64
Z	4
Т (К)	100
ρ (g cm ⁻¹)	1.2137
λ (Å)	0.71073
μ (mm ⁻¹)	0.08
# measured refl	32900
# unique refl	5923
R _{int}	0.1353
# parameters	210
R(F ²), all refl	0.1907
R _w (F ²), all refl	0.2308
Goodness of fit	0.9793



Crystal data for [**6e**]: $C_{20}H_{24}O_3$, M = 312.41, orthorhombic, space group P $2_1 2_1 2_1 (no. 115)$, a = 8.6911(5)Å, b = 9.1112(4) Å, c = 21.5901(10) Å, Flack parameter = -1.7, V = 1709.64(14) Å³, T = 100 K, Z = 4, $d_c = 1.2137$ g cm⁻³, μ (Mo K α , $\lambda = 0.71073$ Å) = 0.08 mm⁻¹, 32900 reflections collected, 5923 unique [$R_{int} = 0.1353$], which were used in all calculations. Refinement on F², final R(F) = 0.1907, $R_w(F^2) = 0.2308$. CCDC number 1419566.



8. NMR spectra of novel compounds










































































9. UPC² traces












































